Komori
Ono Pharmaceutical (4528) · RiskLower credit concentration and higher trade receivables

Concentration of Credit Risk Among a Small Number of Wholesalers

First written in FY2017. 3 of 9 entries say "Mitigated", first in FY2018. Latest entry: FY2026.

9entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2019OtherFY2022 – FY20232017: 120172018: 120182019: 120192020: 020202021: 120212022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Concentration of sales receivables and credit risk among a small number of business partnersA theme 160 companies write about · 160 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2017: 9 of 63 companies on the "Worse" side.

13 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 160 companies compared. The sentences above are computed from all 160.
Full recordFilings, disclosures and news, newest first
  1. FY2026Lower credit concentration and higher trade receivablesAnnual report

    「Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 69% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥87.229 billion and ¥88.415 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies declined from approximately 72% to approximately 69%, while trade receivables increased from ¥87.229 billion to ¥88.415 billion.
  2. FY2025WorsenedAnnual report

    「Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 72% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥73.319 billion and ¥87.229 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies increased from approximately 70% in the previous year to approximately 72%, while trade receivables also increased from ¥73.319 billion to ¥87.229 billion.
  3. FY2024MitigatedAnnual report

    「Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 70% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥86.297 billion and ¥73.319 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies declined from approximately 71% to approximately 70%, and trade receivables also decreased from ¥86.297 billion to ¥73.319 billion.
  4. FY2023Lower credit concentration and higher trade receivablesAnnual report

    「Revenue from the five largest group companies accounts for approximately 71% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥72.726 billion and ¥86.297 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies declined from approximately 72% to approximately 71%, while trade receivables increased from ¥72.726 billion to ¥86.297 billion.
  5. FY2022Lower credit concentration and higher trade receivablesAnnual report

    「Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 72% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥59.689 billion and ¥72.726 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies declined from approximately 73% in the previous year to approximately 72%, while trade receivables increased from ¥59.689 billion to ¥72.726 billion.
  6. FY2021MitigatedAnnual report

    「Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 73% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥56.591 billion and ¥59.689 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of revenue among the five largest group companies declined from approximately 76% in the previous year to approximately 73%. Trade receivables increased, however, and credit concentration risk remains.
  7. FY2019Quantification of credit concentrationAnnual report

    「Our group's revenue mainly comprises royalty income and sales of products through a small number of wholesalers. Revenue from the five largest group companies, including the parent company and its group companies, accounts for approximately 76% of revenue in the consolidated income statement. Trade receivables from these five largest group companies were ¥56.081 billion and ¥55.140 billion in the previous and current consolidated fiscal years, respectively.」

    The concentration of credit risk among a small number of wholesalers and other customers has been newly quantified, with the five largest group companies accounting for approximately 76% of revenue and their trade receivables also disclosed.
  8. FY2018MitigatedAnnual report

    「As a general principle, our group establishes credit limits and transaction terms based on its credit management rules to mitigate monetary losses arising from defaults by these customers. To reduce concerns over collection, we also monitor payment due dates and outstanding balances for each customer, obtain credit information on major customers from third-party rating agencies, and conduct ongoing credit assessments. No material bad debt losses have been recorded on our group's trade receivables in the past.」

    Although credit risk remains concentrated among a small number of wholesalers, the disclosure states that the group manages credit limits and transaction terms, payment due dates and outstanding balances, and credit assessments based on third-party ratings.
  9. FY2017First statedAnnual report

    「Like other pharmaceutical companies, our group sells products through a small number of wholesalers and is exposed to a concentration of credit risk with these wholesalers. If any of these wholesalers encounters financial difficulties, this could have a material adverse effect on our group's financial results.」

    The disclosure explicitly identifies for the first time the concentration of credit risk arising from the sales structure involving a small number of wholesalers as a risk that could have a material impact if a customer experiences financial difficulties.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 3 of its 9 moves.

333322★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs3×
  3. 2In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials3×
  4. 3Global business expansion and international launches3×
  5. 4Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures3×
  6. 5Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers2×
  7. 6Expansion of Opdivo’s indications and progress in international development and sales2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Concentration of Credit Risk Among a Small Number of Wholesalers | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori